- What is Nuplazid (pimavanserin), and how is it used?
- What are the side effects of Nuplazid (pimavanserin)?
- What is the dosage of Nuplazid (pimavanserin)?
- What drugs interact with Nuplazid (pimavanserin)?
- Is Nuplazid (pimavanserin) safe to use while pregnant or breastfeeding?
- How does Nuplazid (pimavanserin) work?
What is Nuplazid (pimavanserin), and how is it used?
What are the side effects of Nuplazid (pimavanserin)?
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Nuplazid is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
Nuplazid is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported
Nuplazid should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval
Common Adverse Reactions:
What is the dosage of Nuplazid (pimavanserin)?
The recommended dose of Nuplazid is 34 mg, taken orally as two 17 mg strength tablets once daily, without titration.
Nuplazid (pimavanserin) is available as 17 mg strength tablets. The white to off-white, round, coated tablets are debossed on one side with a “P” and “17” on the reverse side.
Nuplazid can be taken with or without food.
What drugs interact with Nuplazid (pimavanserin)?
Class 1A antiarrhythmics:
Class 3 antiarrhythmics:
Strong CYP3A4 Inhibitors:
Strong CYP3A4 Inducers:
Is Nuplazid (pimavanserin) safe to use while pregnant or breastfeeding?
There are no data on Nuplazid use in pregnant women that would allow assessment of the drug-associated risk of major congenital malformations or miscarriage. In animal reproduction studies, no adverse developmental effects were seen when pimavanserin was administered orally to rats or rabbits during the period of organogenesis at doses up to 10- or 12-times the maximum recommended human dose (MRHD) of 34 mg/day, respectively. Administration of pimavanserin to pregnant rats during pregnancy and lactation resulted in maternal toxicity and lower pup survival and body weight at doses which are 2-times the MRHD of 34 mg/day.
There is no information regarding the presence of pimavanserin in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Nuplazid and any potential adverse effects on the breastfed infant from Nuplazid or from the underlying maternal condition.
Latest Medications News
Daily Health News
How does Nuplazid (pimavanserin) work?
The mechanism of action of pimavanserin in the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis is unknown. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.
In vitro, pimavanserin acts as an inverse agonist and antagonist at serotonin 5-HT2A receptors with high binding affinity (Ki value 0.087 nM) and at serotonin 5-HT2C receptors with lower binding affinity (Ki value 0.44 nM). Pimavanserin shows low binding to sigma 1 receptors (Ki value 120 nM) and has no appreciable affinity (Ki value >300 nM), to serotonin 5-HT2B, dopaminergic (including D2), muscarinic, histaminergic, or adrenergic receptors, or to calcium channels.
Nuplazid is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Nuplazid is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
Multimedia: Slideshows, Images & Quizzes
Parkinson's Disease Quiz: Test Your Medical IQ
Parkinson's disease is common among neurodegenerative disorders. Do you know how it works? The causes? The symptoms? Take the...
Parkinson's Disease: Symptoms, Causes, Stages, Treatment
Discover the symptoms, causes, stages, and treatment options for Parkinson's disease. Learn more about the stages of Parkinson's...
Related Disease Conditions
Second Source article from Government...
Parkinson's disease is a slowly progressive neurological disease characterized by a fixed inexpressive face, a tremor at rest,...
Wolff-Parkinson-White syndrome is a condition in which abnormal electrical pathways in the heart cause arrhythmias. Symptoms of...
Parkinson's Disease Clinical Trials
Before participating in a clinical trial for Parkinson's disease consider the risks and the benefits. You should know about who...
Parkinson's Disease: Eating Right
Eating a well-balanced and nutritional diet is very beneficial to people with Parkinson's disease. With a proper diet, our...
Treatment & Diagnosis
Medications & Supplements
Prevention & Wellness
- Are Women With Parkinson's at a Disadvantage?
- Brain Disconnects Spotted in Parkinson's Patients With Visual Hallucinations
- 150-Year-Old Drug May Shorten 'Off' Time for Parkinson's Patients
- Antipsychotic Drugs Tied to Risk of Early Death in Parkinson's Patients
- Blood Test Aims to Detect Parkinson's in Early Stages
- Bee-Venom Acupuncture Shows Promise in Parkinson's
- All Kinds of Exercise May Be Good for Parkinson's
- Berries May Contain Potent Weapon vs. Parkinson's
- Brain Changes May Be Tied to Parkinson's Dementia
- Brain Device May Ease Parkinson's
- Brain 'Pacemaker' Treats Parkinson's
Subscribe to MedicineNet's General Health Newsletter
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
All content from the U.S. Food and Drug Administration prescribing information.